Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Solid Sales for Monoclonal Antibodies in Rheumatoid Arthritis Treatment May Prove Biologics Can Overcome the Patent Cliff

By BiotechDaily International staff writers
Posted on 25 Mar 2013
The market for monocloncal antibodies (mAbs) use in the treatment of rheumatoid arthritis (RA) since 2004 has experienced very significant growth, and it is on the threshold of entering a historically extraordinary scenario over the next six years, according to new market research.

According to healthcare market research company GBI Research (New York, NY, USA), eight mAbs are currently approved, half of which count among the top 10 best-selling drugs worldwide, collectively generating over USD 23 billion in sales in 2011. mAbs Remicade is also the blockbusting pharmaceutical product across the entire industry. The approaching patent cliff seems not likely to knock these popular drugs off their position, in a market that is slow to accept new products.

The first three mAbs to be approved to treat RA—Humira, Remicade, and Enbrel—have consistently dominated RA drug sales since their market entry, in spite of the approval of debatably more effective mAb products since then. GBI analyst Dominic Trewartha stated, “Physicians are likely to exercise great caution when prescribing biologics, in part due to their potentially serious side effects. Rheumatologists in general are also quite conservative in their treatment patterns, which could explain why Remicade, Humira and Enbrel are doing so well, being the first mAbs approved for RA. In contrast, biosimilars are less likely to be prescribed. For this reason, the growth of the global market is expected to continue in spite of the impending patent expiry of three of the four top-selling RA mAbs in the US.”

The RA mAbs market in the United States, Japan, Germany, France, the United Kingdom, Spain, and Italy is expected to grow from USD 11.5 billion in 2011 to USD 15.7 billion by 2018. Mr. He continued, “None of the potential market entrants appear to offer any significant improvements to existing medications, and thus will not dramatically affect the market size in the coming years, leaving Remicade, Humira, and Enbrel to maintain their top-selling RA mAbs status.”

The costs and problems tied to bringing biosimilars to the market is also expected to restrict the number of biosimilars and their impact on drug pricing for RA mAbs, estimated to be as low as 10%.

GBI Research is a provider of business intelligence reports, providing data and forecasts based on the insights of key industry experts with the latest emerging trends.

Related Links:

GBI Research



Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.